When long-termism masquerades

In Long-termism, Rafaty poses both a conundrum and call to action for us all to consider.[i] While the myopia of purely short-sighted activity festers epidemics of all sorts, from disease to environmental degradation to parasitic finance, the seeming infinitude of future-facing work can have its own paralyzing effects. Yet this anxiety should not stop such crucial work from happening. Just the opposite. Rafaty reminds us that “the sobriety of long-term thinking is vital to the development of democracy and civilization”.

Part of the problem of cultivating the longue durée in political and economic matters, however, is that its aspirations and achievements are left to the back pages of our public conversations. The short-termists have their next quarterly earnings report or campaign victory to sustain morale and celebrate momentum. The long-termists need to rescue their voice, plan near-term milestones, and call out both warnings and victories. Bemoaning its absence in our public life isn’t enough.

Picture of Damien Hirst’s ‘Utopia’ from 1992.
Source: Jeremy Riad.

If ever there was an arena of action that required this strategy, it is the one that Rafaty interrogates as a scholar: climate science and policy. One promising example here is the nascent and growing adoption of solar panels. In the U.S., for example, the market for solar panels jumped from just $3 billion in 2009 to $13.4 billion last year. Of the nation’s new generating capacity in 2014, solar accounted for 32 percent, beating coal for the second consecutive year. Partial responsibility lies in policy with a long-term view: the nine-year old U.S. investment tax credit for solar policy.[ii] The other key driver is common to many technology sectors such as mobile phones and computer chips: further business model innovation and falling costs for solar panels and modules unleashes viral adoption and market power. But as with any long-term endeavor, the road itself is steep: solar energy only accounts for only 0.4% of all energy generated in the U.S. Acceleration of a transition to a sustainable, green economy means continuing to take on tough and yes, unapologetic, arguments about the nature of the future. President Obama’s new Clean Power Plan announced in early August is one such attempt.[iii]


But beware of arguments only masquerading as long-termism. Imagine, for example, that solar panels were sold using the following pricing model. Let’s say that a solar executive made the following pitch to a potential government buyer: “Climate change related weather events cause your country $100 billion in environmental costs each year. Our technology will help you solve that problem. Because of the value of this technology to the long-run economy and the anticipated savings from less environmental damage, our price is $100,000 per solar panel.” You later do your research and learn that it costs only $1,000 to make a panel, while reading in the company’s business plan that they hope to turn a $50 billion dollar annual revenue. This means that the firm is hoping to gain a 99x profit margin over the cost of the technology and recoup half of the possible cost savings to society. In the solar technology market, this company likely wouldn’t even make it past development. The firm’s pricing model is not based on the costs of production and demand in the market place, but rather on a logic of transmuting the long-term financial value of societal savings into a winner-takes-all private accrual of wealth for one company. A competitor would beat that firm with a better price, and that’d be the end of the story.

Yet this is the very trend occurring today in the pharmaceutical sector, where monopolist calculations about the future are creating a new logic of Long-Term Value. In this logic, pharmaceutical firms argue that their prices are justified not only because of the cost of risky research and development—which requires government-granted monopoly protection—but also because of anticipated savings that their products, even at high prices, provide health systems in the long run. The industry’s main Washington D.C.-based lobby, Pharmaceutical Research and Manufacturers of America (PhRMA) has put forward the following value proposition: buy and use the medicine now and cut costs by averting further hospitalization and medical procedures down the line. [iv] Breakthrough treatments that offer this chance would indeed be a great boon, a triple-win for patients, companies, and health systems. But this grand bargain is threatened if soaring prices extract significant chunks of this possible savings and lead to restrictions in access to treatment.

The case of Hepatitis C offers one demonstration of this script. Gilead Sciences is currently selling a three-month regimen for Hepatitis C patients priced at approximately $90,000. The medicine is made of two components with a backbone compound called sofosbuvir, and represents a veritable breakthrough for which scientists and researchers of Hepatitis C are justifiably proud. Patients are experiencing cure rates of over 95%, with the virus often eliminated in the first month of treatment. This curative therapy for Hepatitis C ranks as one of modern medicine’s leading scientific marvels. Unfortunately, the financial picture—and the ethical dilemmas it has created—presents a far more troubling picture.

Even after discounts for government systems (given their monopsony-like purchasing power), the drug is still priced upwards of $40,000-50,000 across Europe (including the NHS) as well as in the U.S. state Medicaid system. The figures for treating all eligible patients in the U.S. are staggering: an NIH-sponsored study measured the cost to U.S. payers at $136 billion over the next five years, with $61 billion coming from public funding.[v] Given the sizeable number of patients with the disease—an estimated 230,000 people in the UK and over 3 million in the U.S.—the cost to these systems is potentially enormous even if a small fraction of the sickest patients receive the medicines. What’s the cost of factory production of a single three-month regimen? Researchers at the University of Liverpool estimated it to be between $100-250, based on similar production costs for anti-virals for HIV/AIDS.[vi]

A central argument used to defend Gilead’s prices is rooted in its logic of Long-Term Value. The drugs have been deemed to be cost-effective over the life of the patient versus prior treatments, since patients with Hepatitis C will no longer need expensive liver transplants and hospitalizations related to their illness—costs that can run far past $100,000.[vii] The selling point is: if you pay up now, you’ll see savings over the course of the next decades.


We’d be mistaken, though, to accept the industry’s argument for the virtues of its view of the longue durée. Underneath a veneer of long-term thinking hides a more pernicious pathology of short-termism. In just the first year of sales, sofosbuvir-based treatments garnered Gilead Sciences $12.4 billion in revenue, with a sizable portion coming from government-funded spending via Medicaid, Medicare, and the Veteran’s Affairs administration.[viii] Juxtaposed to this expense: a CDC-led research study pegged the annual hospital expenses of Hepatitis C patients on a range between $6.5 billion in 2011 to a peak of $9.1 billion in 2024.[ix] Yet if Gilead’s revenue from sofosbuvir-based regimens simply remains in the vicinity of $10 billion per year in the years to come (which is a real possibility), they will have accrued a major portion of those possible savings. An economic analysis done for the state of California by the Institute for Clinical and Economic Review also found that in a hypothetical situation where every Hepatitis C patient received treatment, “even after 20 years, less than half of the initial cost would be offset by savings from reduced liver complications”.[x] In short: Gilead has already recouped the cost of its initial $11 billion investment—the result of a speculative acquisition—and is also on schedule to capture much of the anticipated long-term value to society into vast private wealth for their company and its shareholders.

The most important reason for treating a patient—their chance at health—is lost amid all the arithmetic. The consequences are significant. Because of the price, most U.S. state Medicaid systems have placed restrictions on the treatment so that only patients with advanced progression of disease and a higher chance of death in the next 1-2 years are eligible.[xi] American veterans, who receive their health care from the publicly funded Veterans Affairs administration, are confronted with a similar fate.[xii]  A large majority of patients, often experiencing felt-illness and increased risks of complications because of chronic liver inflammation, are waiting. Meanwhile, the disguise of long-termism currently wrapped around the debate has placed a rhetorical stranglehold on the advocacy of health systems and patient groups on expanding treatment access.

Long-termism as a universal precept is fraught, then, unless applied to the realities of the particular case, whether it’s a specific policy domain, technology, or person. In matters of health and illness, for example, arguments about the future require peeling back any disguise. J.M Keynes’ simple insight into economics and human life offers a caution relevant for this tale. Admonishing his peers, Keynes argued that economic models that only focused on the long-term were useless—and an excuse for avoiding action—unless accompanied by an analysis of the near-term consequences:


“But this long run is a misleading guide to current affairs. In the long run we are all dead. Economists set themselves too easy, too useless a task if in tempestuous seasons they can only tell us that when the storm is long past the ocean is flat again.”[xiii]


For patients, living with the peace of health—‘where the ocean is flat again’—is what really matters. Forcing them to wait through the long storm of illness shouldn’t be our answer.



[i] Ryan Rafaty, Long-termism”. King’s Review. July 28, 2015.

[ii] “Solar Power Sees Unprecedented Boom in the US”. Scientific American. March 10, 2015.

[iii] David Biello. “How Far Does Obama’s Clean Power Plan Go in Slowing Climate Change?” Scientific American. August 6, 2015.

[iv] PhRMA, “Health care costs”. Accessed August 2, 2015.

[v] Chhatwal et al. “Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir and Ledipasvir in the United States.” Annals of Internal Medicine. March 17, 2015.

[vi] Hill, et al. “Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries.” Clinical Infectious Diseases. January 6, 2014.


[vii] John LaMattina, “Forgotten in the Sovaldi Price Debate: Hep C Patients and Healthcare Savings”. Forbes. June 25, 2014.

[viii] Andrew Pollack. “Sales of Sovaldi, new Gilead Hepatitis C Drug, Soar to 10.3 billion”. New York Times. Feb 3, 2015.

[ix] Razavi, et al. “Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States”. Hepatology. June 2013.


[x] “CTAF Releases Final Report and Action Guides on ‘Newest Treatments for Hepatitis C, Genotype 1’”. Institute for Clinical and Economic Review. February 2015.

[xi] Joseph Walker. “Gilead’s $1,000 pill is hard for states to swallow”. Wall Street Journal. April 8, 2015.

[xii] Gerald Flynn. “The VA’s Hepatitis Problem”. Newsweek. May 9, 2015.

[xiii] Paul Krugman. “Keynes, Keynesians, the Long Run, and Fiscal Policy”. New York Times. May 4, 2013.

Victor Roy is a MD candidate at Northwestern University and a PhD candidate in sociology and political economy at University of Cambridge. He is currently writing a history of the technological innovation, valuation, and ethics behind new curative therapies for patients with Hepatitis C.